Moderna (NASDAQ: ARNM) had a year.
Developing a vaccine that could help end a pandemic apparently has a way of driving up a company’s stock price. So how much luck has Moderna produced for its shareholders in 2020? Let’s review.
Moderna delivered a much needed silver lining to the world in November, when a Phase 3 clinical trial showed its coronavirus vaccine candidate, mRNA-1273, to be 94.1% effective against COVID-19 – and up to 100% effective in preventing severe cases of the disease.
In addition, Moderna’s vaccine was found to be generally safe and well tolerated, with no serious safety concerns identified among the more than 30,000 study participants.
The world applauded. And investors responded by bidding on shares of Moderna, which were already up sharply since the start of the year due to earlier progress in its efforts to develop coronavirus vaccines.
In total, at 11:45 am EST on December 31, Moderna’s stock price rose 446% in 2020. So for every $ 1,000 you invested in Moderna in January, you would have nearly 5,500 $ today.
Still, even larger gains could be expected for Moderna investors in 2021. The biotech company plans to use the profits it earns from sales of mRNA-1273 to fund the development of new vaccines against others. diseases. If one or more of them prove to be safe and effective, Moderna – and its shareholders – could have many good years to come.